Somatic gene therapy remains technically challenging,especially in the central nervous system(CNS).Efficiency of gene delivery,efficacy in recipient cells,and proportion of cells required for overall benefit are the k...Somatic gene therapy remains technically challenging,especially in the central nervous system(CNS).Efficiency of gene delivery,efficacy in recipient cells,and proportion of cells required for overall benefit are the key points needed to be considered in any therapeutic approach.Recent efforts have demonstrated the efficacy of RNA-guided nucleases such as CRISPR/Cas9 in correcting point mutations or removing dominant mutations.Here we used viral delivered Cas9 plasmid and two guide RNAs to remove a recessive insertional mutation,vibrator(vb),in the mouse brain.The vb mice expressed∼20%of normal levels of phosphatidylinositol transfer protein,α(PITPα)RNA and protein due to an endogenous retrovirus inserted in intron 4,resulting in early-onset tremor,degeneration of brainstem and spinal cord neurons,and juvenile death.The in situ CRISPR/Cas9 viral treatment effectively delayed neurodegeneration,attenuated tremor,and bypassed juvenile death.Our studies demonstrate the potential of CRISPR/Cas9-mediated gene therapy for insertional mutations in the postnatal brain.展开更多
Retinal degenerative diseases are a major cause of blindness.Retinal gene therapy is a trail-blazer in the human gene therapy field,leading to the frst FDA approved gene therapy product for a human genetic disease.The...Retinal degenerative diseases are a major cause of blindness.Retinal gene therapy is a trail-blazer in the human gene therapy field,leading to the frst FDA approved gene therapy product for a human genetic disease.The application of Clustered Regularly Interspaced Short Palindromic Repeat/Cas9(CRISPR/Cas9)-mediated gene editing technology is transforming the delivery of gene therapy.We review the history,present,and future pro-spects of retinal gene therapy.展开更多
The Future Forum,a non-profit organization established last year in Beijing,announced that pathologist Dennis Ming Yuk Lo from the Chinese University of Hong Kong won the life sciences Future Science Prize for the dis...The Future Forum,a non-profit organization established last year in Beijing,announced that pathologist Dennis Ming Yuk Lo from the Chinese University of Hong Kong won the life sciences Future Science Prize for the discovery of fetal cell-free DNA(cfDNA)in maternal plasma in 1997(Lo et al.,1997).By detecting male fetus-derived Y sequences in maternal plasma,Lo et al.successfully proved the presence of fetal cfDNA in maternal plasma and serum(Lo et al.,1997).This discovery has opened up a tremendous breadth of展开更多
基金This research was funded by the National Natural Science Foundation of China(grant No.3201101229)Macao Science and Technology Development Fund(grant No.015/2017/AFJ)Natural Science Foundation of Guangdong Province(grant No.2020A1515010072).
文摘Somatic gene therapy remains technically challenging,especially in the central nervous system(CNS).Efficiency of gene delivery,efficacy in recipient cells,and proportion of cells required for overall benefit are the key points needed to be considered in any therapeutic approach.Recent efforts have demonstrated the efficacy of RNA-guided nucleases such as CRISPR/Cas9 in correcting point mutations or removing dominant mutations.Here we used viral delivered Cas9 plasmid and two guide RNAs to remove a recessive insertional mutation,vibrator(vb),in the mouse brain.The vb mice expressed∼20%of normal levels of phosphatidylinositol transfer protein,α(PITPα)RNA and protein due to an endogenous retrovirus inserted in intron 4,resulting in early-onset tremor,degeneration of brainstem and spinal cord neurons,and juvenile death.The in situ CRISPR/Cas9 viral treatment effectively delayed neurodegeneration,attenuated tremor,and bypassed juvenile death.Our studies demonstrate the potential of CRISPR/Cas9-mediated gene therapy for insertional mutations in the postnatal brain.
文摘Retinal degenerative diseases are a major cause of blindness.Retinal gene therapy is a trail-blazer in the human gene therapy field,leading to the frst FDA approved gene therapy product for a human genetic disease.The application of Clustered Regularly Interspaced Short Palindromic Repeat/Cas9(CRISPR/Cas9)-mediated gene editing technology is transforming the delivery of gene therapy.We review the history,present,and future pro-spects of retinal gene therapy.
文摘The Future Forum,a non-profit organization established last year in Beijing,announced that pathologist Dennis Ming Yuk Lo from the Chinese University of Hong Kong won the life sciences Future Science Prize for the discovery of fetal cell-free DNA(cfDNA)in maternal plasma in 1997(Lo et al.,1997).By detecting male fetus-derived Y sequences in maternal plasma,Lo et al.successfully proved the presence of fetal cfDNA in maternal plasma and serum(Lo et al.,1997).This discovery has opened up a tremendous breadth of
